Psychotic Disorders - Botswana | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$3.39m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.95%, resulting in a market volume of US$3.56m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$155.40 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Botswana is experiencing steady growth due to increasing customer preferences for effective and accessible treatments, as well as the presence of local special circumstances that contribute to the development of the market. Customer preferences in the Psychotic Disorders market in Botswana are primarily focused on treatments that are both effective and accessible. Customers are seeking medications and therapies that can effectively manage their symptoms and improve their quality of life. They also value treatments that are easily accessible, as many individuals with psychotic disorders may face challenges in accessing healthcare services. As a result, there is a growing demand for medications and therapies that can be easily obtained and administered in Botswana.Trends in the market include the introduction and adoption of new medications and therapies for psychotic disorders. Pharmaceutical companies are investing in research and development to create innovative treatments that can effectively manage symptoms and improve patient outcomes. These new medications and therapies are being introduced into the market, providing customers with more options for treatment. Additionally, there is a growing trend towards holistic approaches to treatment, which may include a combination of medication, therapy, and lifestyle modifications.Local special circumstances in Botswana contribute to the development of the Psychotic Disorders market. The country has a high prevalence of mental health disorders, including psychotic disorders, which creates a significant demand for treatment options. Additionally, Botswana has a well-established healthcare system that provides access to healthcare services for its citizens. This infrastructure supports the growth of the Psychotic Disorders market by ensuring that individuals can receive the necessary treatments and support.Underlying macroeconomic factors also play a role in the development of the Psychotic Disorders market in Botswana. The country has experienced steady economic growth in recent years, which has led to an increase in disposable income and healthcare spending. As a result, individuals are able to afford the medications and therapies needed to manage their psychotic disorders. Furthermore, the government of Botswana has implemented policies and initiatives to improve mental healthcare services, including the integration of mental health into primary care settings. These efforts contribute to the overall growth and development of the Psychotic Disorders market in Botswana.In conclusion, the Psychotic Disorders market in Botswana is developing due to customer preferences for effective and accessible treatments, as well as local special circumstances and underlying macroeconomic factors. The market is experiencing trends such as the introduction of new medications and therapies, as well as a shift towards holistic approaches to treatment. With a high prevalence of mental health disorders and a well-established healthcare system, Botswana provides a conducive environment for the growth of the Psychotic Disorders market.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.